Skip to main content
    I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.98
    -0.42 (-2.92%)

    Market Cap: $1.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Integra LifeSciences Holdings (IART) Earnings: Report Dates and Results

    Updated Oct 21, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Integra LifeSciences Holdings (IART) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Integra LifeSciences Holdings reported EPS of $0.59, above the $0.56 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +11.06%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.68
    Range$0.61 - $0.88
    13 analysts
    Revenue Consensus
    $430.84M
    Range$411.70M - $445.20M
    13 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.49
    Range$0.41 - $0.60
    8 analysts
    EPS Estimate DriftChange to current
    90d ago$0.54-7.8%
    60d ago$0.54-7.8%
    30d ago$0.54-7.8%
    7d ago$0.490.0%
    Current$0.49
    Revenue Consensus
    $388.16M
    Range$383.71M - $395.12M
    6 analysts

    Next Report

    IART has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 18.1% below the $0.83 reported for the quarter ended Dec 31, 2025.

    IART Earnings Call

    The latest IART earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, IART beat 29, missed 5 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $411.18M, up 2.3% from $402.06M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.59$0.56$0.55 - $0.57+5.36%Beat+9.3%101 up, 2 downOct 21, 2026$411.18M
    Jun 30, 2026$0.56$0.48$0.45 - $0.50+16.67%Beat+24.4%111 up, 5 downJul 29, 2026$418.76M
    Mar 31, 2026$0.54$0.40$0.40 - $0.41+35.00%Beat+31.7%70 up, 7 downMay 5, 2026$391.92M
    Dec 31, 2025$0.83$0.79$0.78 - $0.82+5.06%Beat-14.4%90 up, 1 downFeb 26, 2026$434.93M
    Sep 30, 2025$0.54$0.43$0.42 - $0.45+25.58%Beat+31.7%100 up, 9 downOct 30, 2025$402.06M
    Jun 30, 2025$0.45$0.43$0.42 - $0.46+4.65%Beat-28.6%100 up, 10 downJul 31, 2025$415.61M
    Mar 31, 2025$0.41$0.43$0.41 - $0.45-4.65%Miss-25.5%100 up, 7 downMay 5, 2025$382.65M
    Dec 31, 2024$0.97$0.86$0.83 - $0.87+13.40%Beat+9.0%100 up, 1 downFeb 25, 2025$442.65M
    Sep 30, 2024$0.41$0.39$0.35 - $0.42+5.13%Beat-46.1%120 up, 0 downNov 4, 2024$380.83M
    Jun 30, 2024$0.63$0.62$0.60 - $0.64+1.61%Beat-11.3%110 up, 0 downJul 29, 2024$418.18M
    Mar 31, 2024$0.55$0.55$0.53 - $0.580.00%In line-25.7%120 up, 0 downMay 6, 2024$368.87M
    Dec 31, 2023$0.89$0.90$0.89 - $0.92-1.11%Miss-5.3%110 up, 0 downFeb 28, 2024$397.04M
    Sep 30, 2023$0.76$0.78$0.76 - $0.79-2.56%Miss-11.6%111 up, 0 downOct 25, 2023$382.42M
    Jun 30, 2023$0.71$0.57$0.56 - $0.59+24.56%Beat-13.4%110 up, 1 downJul 26, 2023$381.27M
    Mar 31, 2023$0.74$0.74$0.72 - $0.750.00%In line0.0%110 up, 0 downApr 26, 2023$380.85M
    Dec 31, 2022$0.94$0.90$0.89 - $0.94+4.44%Beat+11.9%122 up, 0 downFeb 22, 2023$398.02M
    Sep 30, 2022$0.86$0.72$0.69 - $0.80+19.44%Beat0.0%110 up, 3 downOct 26, 2022$385.19M
    Jun 30, 2022$0.82$0.80$0.79 - $0.81+2.50%Beat+3.8%100 up, 1 downJul 27, 2022$397.81M
    Mar 31, 2022$0.74$0.68$0.65 - $0.69+8.82%Beat+7.2%120 up, 0 downApr 27, 2022$376.64M
    Dec 31, 2021$0.84$0.83$0.81 - $0.85+1.20%Beat0.0%131 up, 0 downFeb 23, 2022$405.52M
    Sep 30, 2021$0.86$0.72$0.71 - $0.75+19.44%Beat+7.5%130 up, 0 downNov 2, 2021$386.86M
    Jun 30, 2021$0.79$0.66$0.65 - $0.69+19.70%Beat+139.4%13N/AJul 28, 2021$389.99M
    Mar 31, 2021$0.69$0.57$0.56 - $0.58+21.05%Beat+43.7%13N/AApr 28, 2021$360.07M
    Dec 31, 2020$0.84$0.73$0.69 - $0.87+15.07%Beat+23.5%13N/AFeb 18, 2021$388.65M
    Sep 30, 2020$0.80$0.54$0.44 - $0.59+48.15%Beat+17.6%13N/AOct 28, 2020$370.23M
    Jun 30, 2020$0.33$0.15-$0.02 - $0.24+120.00%Beat-54.8%12N/AAug 10, 2020$258.67M
    Mar 31, 2020$0.48$0.63$0.55 - $0.69-23.81%Miss-26.2%10N/AMay 7, 2020$354.32M
    Dec 31, 2019$0.68$0.67$0.64 - $0.68+1.49%Beat+4.6%12N/AFeb 19, 2020$395.13M
    Sep 30, 2019$0.68$0.66$0.64 - $0.71+3.03%Beat+15.3%13N/AOct 24, 2019$379.10M
    Jun 30, 2019$0.73$0.66$0.64 - $0.68+10.61%Beat+21.7%14N/AJul 24, 2019$383.64M
    Mar 31, 2019$0.65$0.61$0.59 - $0.63+6.56%Beat+12.1%16N/AApr 24, 2019$359.69M
    Dec 31, 2018$0.65$0.62$0.59 - $0.64+4.84%Beat+1.6%16N/AFeb 21, 2019$383.31M
    Sep 30, 2018$0.59$0.59$0.58 - $0.600.00%In line+31.1%13N/AOct 31, 2018$365.85M
    Jun 30, 2018$0.60$0.60$0.58 - $0.610.00%In line+33.3%14N/AJul 25, 2018$366.19M
    Mar 31, 2018$0.58$0.49$0.48 - $0.51+18.37%Beat+48.7%14N/AApr 25, 2018$357.08M
    Dec 31, 2017$0.64$0.56$0.54 - $0.58+14.29%Beat+23.1%14N/AFeb 27, 2018$368.60M
    Sep 30, 2017$0.45$0.47$0.46 - $0.50-4.26%Miss-4.3%14N/AOct 26, 2017$278.83M
    Jun 30, 2017$0.45$0.45$0.43 - $0.480.00%In line+12.5%15N/AJul 26, 2017$282.16M
    Mar 31, 2017$0.39$0.38N/A+2.63%Beat+5.4%N/AN/AApr 26, 2017$258.64M
    Dec 31, 2016$0.52$0.52N/A0.00%In line+18.2%N/AN/AFeb 23, 2017$255.66M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.23, down 12.9% from the year before. It was $1.76 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.23-12.9%
    Dec 31, 2024$2.56-17.4%
    Dec 31, 2023$3.10-7.7%
    Dec 31, 2022$3.36+5.7%
    Dec 31, 2021$3.18+29.8%
    Dec 31, 2020$2.45-10.6%
    Dec 31, 2019$2.74+13.2%
    Dec 31, 2018$2.42+25.4%
    Dec 31, 2017$1.93+9.7%
    Dec 31, 2016$1.76N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,900 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,90313
    2026Q2Jun 30, 20265,51611
    2026Q1Mar 31, 20267,41512
    2025Q4Dec 31, 20254,5777
    2025Q3Sep 30, 20255,4189
    2025Q2Jun 30, 20255,5559
    2025Q1Mar 31, 20256,88312
    2024Q4Dec 31, 20247,08113

    2026Q3 Earnings Call

    Opening remarks

    Chris Ward Senior Director, Investor Relations Good morning, and thank you for joining the Integra LifeSciences third quarter 2026 earnings conference call. Joining me on the call are Stuart Essig, Chairman and Chief Executive Officer, and Lea Knight, Chief Financial Officer. We issued a press release this morning announcing our third quarter 2026 financial results. The release and earnings presentation we reference during the call are available at integralife.com under Investors, Events and Presentations in a file named Third Quarter 2026 Earnings Presentation. Before we begin, I want to remind you that many statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports that we filed with the SEC. These factors are also detailed in the release. Also, in our prepared remarks, we will reference reported and organic revenue growth. Organic revenue growth excludes the effects of foreign currency, acquisitions, and divestitures. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures are included in today's press release, which is an exhibit to Integra's current report on Form 8-K filed today with the SEC. With that, I will now turn the call over to Stuart.

    Stuart Essig Chairman and CEO Good morning, everyone, and thank you for joining us. As many of you know, we provided preliminary third quarter 2026 financial results and an updated full-year 2026 outlook on October 2 in conjunction with the initiation of our refinancing. We recognize that the update was disappointing, particularly because it came against a backdrop of meaningful progress for the company during the year. Today, I want to provide more context on our third quarter performance, the factors that shaped our updated outlook, and our priorities as we look ahead to 2027. For the third quarter, we delivered revenue of $411 million, which was at the low end of our guidance range. During the quarter, the Cincinnati disruption proved more significant than initially expected, and growth in Tissue Reconstruction did not materialize as anticipated. At the same time, upside in neurosurgery offset much of those headwinds. We delivered adjusted earnings per share of $0.59 and generated $96 million of operating cash flow. We also reduced leverage to 3.8 times, and subsequent to the end of the quarter, we successfully completed a debt refinancing. The quarter's strong cash generation, lower leverage, and successful refinancing have strengthened our balance sheet and increased our financial flexibility. Together, these are important indicators of the progress we are making to improve Integra's overall financial profile and support continued execution of our priorities.

    Frequently Asked Questions About IART

    When is Integra LifeSciences Holdings's next earnings date?

    Integra LifeSciences Holdings's next earnings report is expected for Feb 24, 2027.

    Did IART beat earnings estimates last quarter?

    Yes. Integra LifeSciences Holdings reported EPS of $0.59 for the quarter ended Sep 30, 2026, above the $0.56 estimate, a 5.36% surprise.

    What EPS do analysts expect from IART next quarter?

    The consensus EPS estimate for Integra LifeSciences Holdings for the quarter ending Dec 31, 2026 is $0.68 from 13 analysts, with estimates from $0.61 to $0.88.

    How often does IART beat earnings estimates?

    Integra LifeSciences Holdings beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +12.63%.